ConductScience.org, home

Paper36701088

Apheresis: What Should a Clinician Know?

Parhofer KG. Curr Atheroscler Rep, 2023. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Apheresis: What Should a Clinician Know? Papers, record 36701088. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36701088

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Apheresis: What Should a Clinician Know?
PubMed
Journal
Curr Atheroscler Rep
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.7
iCite
Revised in PubMed
2023-05-04
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Parhofer KGKlaus Ghttps://orcid.org/0000-0001-9873-0412

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hyperlipoproteinemia Type IIMajor topic
Homozygous Familial HypercholesterolemiaMajor topic
Blood Component RemovalMajor topic
Humans
Cholesterol, LDL
Lipoprotein(a)

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127572070Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.Eur Heart J2016https://conductscience.org/library/papers/27572070PubMed
235718549Effect of Lipoprotein Apheresis on Progression of Carotid Intima-Media Thickness in Patients with Severe Hypercholesterolemia.Am J Cardiol2022https://conductscience.org/library/papers/35718549PubMed
334472586
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.
Eur Heart J2021https://conductscience.org/library/papers/34472586PubMed
448833Plasma exchange in the management of homozygous familial hypercholesterolaemia.Lancet1975https://conductscience.org/library/papers/48833PubMed
57898227Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.Lancet1995https://conductscience.org/library/papers/7898227PubMed
624056686
Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
Circulation2013https://conductscience.org/library/papers/24056686PubMed
721834078Lipid apheresis, indications, and principles.J Clin Apher2011https://conductscience.org/library/papers/21834078PubMed
823889507Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?Artif Organs2014https://conductscience.org/library/papers/23889507PubMed
931041550Current Role of Lipoprotein Apheresis.Curr Atheroscler Rep2019https://conductscience.org/library/papers/31041550PubMed
1020935563Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe.Curr Opin Lipidol2010https://conductscience.org/library/papers/20935563PubMed
1130058841From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.Eur J Prev Cardiol2018https://conductscience.org/library/papers/30058841PubMed
1230611543Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a).Pathology2019https://conductscience.org/library/papers/30611543PubMed
1318371971Recommendations for the use of LDL apheresis.Atherosclerosis2008https://conductscience.org/library/papers/18371971PubMed
14315044182019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.Eur Heart J2020https://conductscience.org/library/papers/31504418PubMed
1531280466PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice.Drugs Real World Outcomes2019https://conductscience.org/library/papers/31280466PubMed
1631753721Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease.J Clin Lipidol2019https://conductscience.org/library/papers/31753721PubMed
179874053Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.Am J Cardiol1998https://conductscience.org/library/papers/9874053PubMed
1829096836Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.Atheroscler Suppl2017https://conductscience.org/library/papers/29096836PubMed
191827976Immunosorbent for selective removal of lipoprotein (a) from human plasma: in vitro study.Artif Organs1991https://conductscience.org/library/papers/1827976PubMed
2026889050Lipoprotein apheresis to treat elevated lipoprotein (a).J Lipid Res2016https://conductscience.org/library/papers/26889050PubMed

See all 28 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42461299[Austrian lipid consensus : Interdisciplinary evidence-based recommendations on prevention and treatment of lipid-associated diseases from 15 medical specialist societies].Wien Klin Wochenschr2026https://conductscience.org/library/papers/42461299PubMed
42124773Lipoprotein(a): Role in Cardiovascular Risk and Advances in Novel Therapeutics.Cureus2026https://conductscience.org/library/papers/42124773PubMed
39769362Reduced Oxidative Susceptibility of Lp(a) and LDL Fractions as a Pleiotropic Effect of Lipoprotein Apheresis in Patients with Elevated Lp(a) and ASCVDs.Int J Mol Sci2024https://conductscience.org/library/papers/39769362PubMed
38436784Updates on Non-Statin LDL-Lowering Therapy.Curr Cardiol Rep2024https://conductscience.org/library/papers/38436784PubMed
37799590
Case report: lipoprotein apheresis reduces the risk of cardiovascular events and prolongs pregnancy in a woman with severely elevated lipoprotein(a), cardiovascular disease, and a high risk of preeclampsia.
Front Med (Lausanne)2023https://conductscience.org/library/papers/37799590PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
APOB338PubTator's text mininghttps://conductscience.org/library/genes/338NCBI Gene
LPA4018PubTator's text mininghttps://conductscience.org/library/genes/4018NCBI Gene
PCSK9255738PubTator's text mininghttps://conductscience.org/library/genes/255738NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36701088

GET https://conductscience.org/api/papers/v1/36701088/references?page=2